Healthcare Providers and Services
Company Overview of Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center is a cancer care hospital that engages in cancer prevention, treatment, research, and education. It offers a range of programs to help patients and families throughout various phases of treatment, including genetic counseling, rehabilitation, integrative medicine, counseling, pain and palliative care, cancer screening, and assistance in navigating life after treatment. The company provides childhood cancer treatments, including blood and marrow transplantation, pediatric surgery, and subspecialty services; and treatments for adolescents and young adults with various types of cancers. Its research areas include cancer biology and genetics, cell biology, ...
1275 York Avenue
New York, NY 10065
Founded in 1884
Key Executives for Memorial Sloan Kettering Cancer Center
Chief Executive Officer and President
Senior Vice President of Finance
Chief Investment Officer and Vice President
Chief Information Officer and Vice President of Information Systems
Compensation as of Fiscal Year 2016.
Memorial Sloan Kettering Cancer Center Key Developments
Avacta Group plc Announces the Research Collaboration with Memorial Sloan Kettering Cancer Center
Nov 2 16
Avacta Group Plc announced a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate the use of Avacta's Affimer technology in novel CAR-T cell-based immunotherapy. CAR-T immunotherapy is a form of cancer treatment in which the patient's own immune system T cells are modified to give them greater potency with which to attack cancer cells. Treatments using these engineered immune cells have generated promising responses in patients with advanced cancers and CAR-T immunotherapy has become an intense area of research, clinical development and investment. As part of the collaboration Avacta will develop Affimer molecules that bind different regions of CD19, a surface protein specific to B-cells involved in lymphomas. Dr. Brentjens' team will construct CAR-T cells incorporating these Affimer molecules and test their anti-tumour function in vitro and in vivo animal efficacy models. Under the terms of the agreement the ownership of the results generated directly as part of this collaboration will be shared between Avacta and MSK.
Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd., Bay City Capital and Deerfield Management Announce the Establishment of a New Drug Discovery Company
Oct 31 16
Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases. Bridge Medicines builds upon the work of the independent, non-profit Tri-Institutional Therapeutics Discovery Institute, known as Tri-I TDI. Scientists at the Tri-I TDI, which launched in 2013, are working in the laboratory on approximately 50 early-stage drug discovery projects, spanning therapeutic areas including infectious disease, oncology, neuropsychiatry and rare diseases, with the hope that they might be translated into future treatments for patients. Research projects accepted into the Tri-I TDI will now be able to graduate to Bridge Medicines, where they will be given financial, operational and managerial support to move seamlessly from a validating, proof-of-concept study to an in-human clinical trial. Typically, investigators behind promising early-stage discoveries must search for a biopharmaceutical company to purchase or license their intellectual property, or find a funding opportunity to support additional research. This process can be time consuming and may shift investigators' focus away from science, slowing down and in some cases ending the development path.
Memorial Sloan Kettering Cancer Center Presents at The Cell & Gene Meeting on the Mesa, Oct-07-2016 04:20 PM
Oct 4 16
Memorial Sloan Kettering Cancer Center Presents at The Cell & Gene Meeting on the Mesa, Oct-07-2016 04:20 PM. Venue: La Jolla, CA 92037, United States. Speakers: Lorenz Studer, Director, Center for Stem Cell Biology.
Similar Private Companies By Industry
Recent Private Companies Transactions